|
1
|
Cassiman D and Jaeken J: NASH may be
trash. Gut. 57:141–144. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Powell EE, Cooksley WG, Hanson R, Searle
J, Halliday JW and Powell LW: The natural history of nonalcoholic
steatohepatitis: A follow-up study of forty-two patients for up to
21 years. Hepatology. 11:74–80. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Harrison SA, Torgerson S and Hayashi PH:
The natural history of nonalcoholic fatty liver disease: A clinical
histopathological study. Am J Gastroenterol. 98:2042–2047. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Cohen JC, Horton JD and Hobbs HH: Human
fatty liver disease: Old questions and new insights. Science.
332:1519–1523. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Bedogni G, Miglioli L, Masutti F,
Tiribelli C, Marchesini G and Bellentani S: Prevalence of and risk
factors for nonalcoholic fatty liver disease: The Dionysos
nutrition and liver study. Hepatology. 42:44–52. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Blachier M, Leleu H, Peck-Radosavljevic M,
Valla DC and Roudot-Thoraval F: The burden of liver disease in
Europe: A review of available epidemiological data. J Hepatol.
58:593–608. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Sanyal AJ; American Gastroenterological
Association, : AGA technical review on nonalcoholic fatty liver
disease. Gastroenterology. 123:1705–1725. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Neuschwander-Tetri BA: Nonalcoholic
steatohepatitis and the metabolic syndrome. Am J Med Sci.
330:326–335. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Le Goff C and Cormier-Daire V: The
ADAMTS(L) family and human genetic disorders. Hum Mol Genet.
20:R163–R167. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Uemura M, Tatsumi K, Matsumoto M, Fujimoto
M, Matsuyama T, Ishikawa M, Iwamoto TA, Mori T, Wanaka A, Fukui H
and Fujimura Y: Localization of ADAMTS13 to the stellate cells of
human liver. Blood. 106:922–924. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Watanabe N, Ikeda H, Kume Y, Satoh Y,
Kaneko M, Takai D, Tejima K, Nagamine M, Mashima H, Tomiya T, et
al: Increased production of ADAMTS13 in hepatic stellate cells
contributes to enhanced plasma ADAMTS13 activity in rat models of
cholestasis and steatohepatitis. Thromb Haemost. 102:389–396.
2009.PubMed/NCBI
|
|
12
|
Uemura M, Fujimura Y, Ko S, Matsumoto M,
Nakajima Y and Fukui H: Pivotal role of ADAMTS13 function in liver
diseases. Int J Hematol. 91:20–29. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Takaya H, Uemura M, Fujimura Y, Matsumoto
M, Matsuyama T, Kato S, Morioka C, Ishizashi H, Hori Y, Fujimoto M,
et al: ADAMTS13 activity may predict the cumulative survival of
patients with liver cirrhosis in comparison with the
Child-Turcotte-Pugh score and the model for end-stage liver disease
score. Hepatol Res. 42:459–472. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Uemura M, Matsuyama T, Ishikawa M,
Fujimoto M, Kojima H, Sakurai S, Ishii S, Toyohara M, Yamazaki M,
Yoshiji H, et al: Decreased activity of plasma ADAMTS13 may
contribute to the development of liver disturbance and multiorgan
failure in patients with alcoholic hepatitis. Alcohol Clin Exp Res.
29 12 Suppl:264S–271S. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Matsumoto M, Kawa K, Uemura M, Kato S,
Ishizashi H, Isonishi A, Yagi H, Park YD, Takeshima Y, Kosaka Y, et
al: Prophylactic fresh frozen plasma may prevent development of
hepatic VOD after stem cell transplantation via ADAMTS13-mediated
restoration of von Willebrand factor plasma levels. Bone Marrow
Transplant. 40:251–259. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ikeda H, Tateishi R, Enooku K, Yoshida H,
Nakagawa H, Masuzaki R, Kondo Y, Goto T, Shiina S, Kume Y, et al:
Prediction of hepatocellular carcinoma development by plasma
ADAMTS13 in chronic hepatitis B and C. Cancer Epidemiol Biomarkers
Prev. 20:2204–2211. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Motto DG, Chauhan AK, Zhu G, Homeister J,
Lamb CB, Desch KC, Zhang W, Tsai HM, Wagner DD and Ginsburg D:
Shigatoxin triggers thrombotic thrombocytopenic purpura in
genetically susceptible ADAMTS13-deficient mice. J Clin Invest.
115:2752–2761. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
18
|
de Maeyer B, de Meyer SF, Feys HB, Pareyn
I, Vandeputte N, Deckmyn H and Vanhoorelbeke K: The distal
carboxyterminal domains of murine ADAMTS13 influence proteolysis of
platelet-decorated VWF strings in vivo. J Thromb Haemost.
8:2305–2312. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Council NR: Guide for the Care and Use
Laboratoy Animals. 7th. Washington, DC: National Academy Press;
1996
|
|
20
|
Kleiner DE, Brunt EM, van Natta M, Behling
C, Contos MJ, Cummings OW, Ferrell LD, Liu YC, Torbenson MS,
Unalp-Arida A, et al: Design and validation of a histological
scoring system for nonalcoholic fatty liver disease. Hepatology.
41:1313–1321. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Verbeek J, Lannoo M, Pirinen E, Ryu D,
Spincemaille P, Elst I Vander, Windmolders P, Thevissen K, Cammue
BP, van Pelt J, et al: Roux-en-y gastric bypass attenuates hepatic
mitochondrial dysfunction in mice with non-alcoholic
steatohepatitis. Gut. 64:673–683. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Bedossa P, Poitou C, Veyrie N, Bouillot
JL, Basdevant A, Paradis V, Tordjman J and Clement K:
Histopathological algorithm and scoring system for evaluation of
liver lesions in morbidly obese patients. Hepatology. 56:1751–1759.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Bedossa P, Dargère D and Paradis V:
Sampling variability of liver fibrosis in chronic hepatitis C.
Hepatology. 38:1449–1457. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2 (−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Verhenne S, Denorme F, Libbrecht S,
Vandenbulcke A, Pareyn I, Deckmyn H, Lambrecht A, Nieswandt B,
Kleinschnitz C, Vanhoorelbeke K and De Meyer SF: Platelet-derived
VWF is not essential for normal thrombosis and hemostasis but
fosters ischemic stroke injury in mice. Blood. 126:1715–1722. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Deforche L, Tersteeg C, Roose E,
Vandenbulcke A, Vandeputte N, Pareyn I, de Cock E, Rottensteiner H,
Deckmyn H, De Meyer SF and Vanhoorelbeke K: Generation of
anti-murine ADAMTS13 antibodies and their application in a mouse
model for acquired thrombotic thrombocytopenic purpura. PLoS One.
11:e01603882016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Murrin RJ and Murray JA: Thrombotic
thrombocytopenic purpura: Aetiology, pathophysiology and treatment.
Blood Rev. 20:51–60. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Geys L, Scroyen I, Roose E, Vanhoorelbeke
K and Lijnen HR: ADAMTS13 deficiency in mice does not affect
adipose tissue development. Biochim Biophys Acta. 1850:1368–1374.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Geys L, Bauters D, Roose E, Tersteeg C,
Vanhoorelbeke K, Hoylaerts MF, Lijnen RH and Scroyen I: ADAMTS13
deficiency promotes microthrombosis in a murine model of
diet-induced liver steatosis. Thromb Haemost. 117:19–26. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Lombardi AM, Fabris R, de Marinis G Berti,
Marson P, Navaglia F, Plebani M, Vettor R and Fabris F: Defective
ADAMTS13 synthesis as a possible consequence of NASH in an obese
patient with recurrent thrombotic thrombocytopenic purpura. Eur J
Haematol. 92:497–501. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Hugenholtz GC, Adelmeijer J, Meijers JC,
Porte RJ, Stravitz RT and Lisman T: An unbalance between von
Willebrand factor and ADAMTS13 in acute liver failure: Implications
for hemostasis and clinical outcome. Hepatology. 58:752–761. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Takahashi Y, Soejima Y and Fukusato T:
Animal models of nonalcoholic fatty liver disease/nonalcoholic
steatohepatitis. World J Gastroenterol. 18:2300–2308. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Machado MV, Michelotti GA, Xie G, Pereira
T Almeida, Boursier J, Bohnic B, Guy CD and Diehl AM: Mouse models
of diet-induced nonalcoholic steatohepatitis reproduce the
heterogeneity of the human disease. PLoS One. 10:e01279912015.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Caballero F, Fernández A, Matías N,
Martínez L, Fucho R, Elena M, Caballeria J, Morales A,
Fernández-Checa JC and García-Ruiz C: Specific contribution of
methionine and choline in nutritional nonalcoholic steatohepatitis:
Impact on mitochondrial S-adenosyl-L-methionine and glutathione. J
Biol Chem. 285:18528–18536. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Rinella ME, Elias MS, Smolak RR, Fu T,
Borensztajn J and Green RM: Mechanisms of hepatic steatosis in mice
fed a lipogenic methionine choline-deficient diet. J Lipid Res.
49:1068–1076. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Weltman MD, Farrell GC and Liddle C:
Increased hepatocyte CYP2E1 expression in a rat nutritional model
of hepatic steatosis with inflammation. Gastroenterology.
111:1645–1653. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Weltman MD, Farrell GC, Hall P,
Ingelman-Sundberg M and Liddle C: Hepatic cytochrome P450 2E1 is
increased in patients with nonalcoholic steatohepatitis.
Hepatology. 27:128–133. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Rinella ME and Green RM: The
methionine-choline deficient dietary model of steatohepatitis does
not exhibit insulin resistance. J Hepatol. 40:47–51. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Fan JG and Qiao L: Commonly used animal
models of non-alcoholic steatohepatitis. Hepatobiliary Pancreat Dis
Int. 8:233–240. 2009.PubMed/NCBI
|
|
40
|
Kirsch R, Clarkson V, Shephard EG, Marais
DA, Jaffer MA, Woodburne VE, Kirsch RE and Pde L Hall: Rodent
nutritional model of non-alcoholic steatohepatitis: Species, strain
and sex difference studies. J Gastroenterol Hepatol. 18:1272–1282.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Bauters D, Spincemaille P, Geys L,
Cassiman D, Vermeersch P, Bedossa P, Scroyen I and Lijnen RH:
ADAMTS5 deficiency protects against non-alcoholic steatohepatitis
(NASH) in obesity. Liver Int. 36:1848–1859. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Pena A Dela, Leclercq I, Field J, George
J, Jones B and Farrell G: NF-kappaB activation, rather than TNF,
mediates hepatic inflammation in a murine dietary model of
steatohepatitis. Gastroenterology. 129:1663–1674. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Leclercq IA, Farrell GC, Field J, Bell DR,
Gonzalez FJ and Robertson GR: CYP2E1 and CYP4A as microsomal
catalysts of lipid peroxides in murine nonalcoholic
steatohepatitis. J Clin Invest. 105:1067–1075. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Ip E, Farrell G, Hall P, Robertson G and
Leclercq I: Administration of the potent PPARalpha agonist,
Wy-14,643, reverses nutritional fibrosis and steatohepatitis in
mice. Hepatology. 39:1286–1296. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Potze W, Siddiqui MS, Boyett SL,
Adelmeijer J, Daita K, Sanyal AJ and Lisman T: Preserved hemostatic
status in patients with non-alcoholic fatty liver disease. J
Hepatol. 65:980–987. 2016. View Article : Google Scholar : PubMed/NCBI
|
